Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Blueprint Medicines' RET inhibitor BLU-667 shows "broad anti-tumour" activity in early-stage study

firstwordpharmaApril 16, 2018

Tag: Blueprint Medicines , anti-tumour

PharmaSources Customer Service